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Purpose: To analyze the visual outcome, systemic associations, effec-
tiveness of treatment and predicting features of 104 scleritis patients. 
Design: Retrospective case series.
Participants: 104 patients treated for scleritis at the University 
Medical Centers of Groningen and Utrecht.
Methods: The clinical records of 104 patients diagnosed with 
scleritis between 1992 and 2011 at the University Medical Centers of 
Groningen, (n= 64) and Utrecht (n=40) were retrospectively analyzed.
Main outcome measures: Loss of visual acuity, ocular complications, 
related systemic disease, type of treatment, time to treatment success 
and predictive features.
Results: Mean age was 51.5 (standard deviation[SD], ±13.6) years, 
63 (60.6 %) patients were female. Mean follow up was 38.2 (SD± 
33.8) months. A loss of more than two lines of Snellen acuity was 
observed in 23 patients, 3 of whom had a final visual acuity of no light 
perception (NLP). In general, patients with necrotizing scleritis (n=15) 
had a poorer outcome. 
Ocular complications were observed in 88 (84.6%) patients. Underlying 
systemic disease was identified in 34 (32.7 %) patients. Steroid-
sparing immunosuppressive medication was used in 47 patients, 
36 of these were treated with methotrexate (MTX). This led was 
successful in 17 (47.2%) patients over the course of a mean ± SD 103.7 
± 83.7 weeks. Mycophenolate mofetil (MMF) was the treatment in 10 
patients, and in 5 patients treatment success was achieved in a mean 
± SD 65.3 ± 37.4 weeks. Treatment with tumor necrosis factor-alpha 
(TNF-α) antagonists led to treatment success in a mean ± SD 32.6 ± 
21.8 weeks in 5 of the 11 treated patients. Patients with loss of visual 
acuity or those treated with oral steroid-sparing immunosuppressive 
drugs had more often an underlying associated disease, a bilateral 
scleritis and a longer period of symptoms at presentation.
Conclusions: Scleritis is a severe ocular inflammation often associated 
with ocular complications. In this population roughly half of the 
patients were treated with systemic immunosuppressive medication. 
MMF and TNF-α antagonists can be used in case of MTX-failure. 
TNF-α antagonists seemed to be more effective than MTX. Within this 
group, an underlying associated disease, a bilateral scleritis and a 
longer period of symptoms at presentation were predictive features 




Scleritis is a rare, usually painful inflammation of the sclera that can threaten 
vision.1 Scleritis is still classified according to the classification proposed by 
Watson and Hayreh2 in 1976 based on anatomic location and appearance (Table 
1). Few patients convert from episcleritis to scleritis,2,3 and only a small group of 
scleritis patients change from one variant of scleritis to another.3 Complications 
such as corneal and scleral thinning, corneal ulcers, serous retinal detachment, 
papilledema, glaucoma, cataract, and uveitis frequently are seen.4,5 In 40% to 
50% of patients, scleritis is an expression of an underlying systemic disease.5 
Rheumatoid arthritis, Wegener’s disease, relapsing polychondritis, systemic 
lupus erythematosus, inflammatory bowel disease, polyarteritis nodosa, and 
seronegative spondylarthropathies5,6 are the most common autoimmune 
causes. In 4% to 18% of patients, an infectious cause is found, of which herpes 
zoster is the most frequent cause, followed by tuberculosis, syphilis, leprosy, 
and Lyme borreliosis.3,5–7 Other causes of scleritis, such as malignancies, 
medication, surgery, and trauma, are reported to be rare in all studies. In general, 
nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed as the first step 
in the treatment of scleritis. In case of unsatisfactory therapeutic response, 
the next step is administration of oral corticosteroids at high doses for a short 
period. If prolonged treatment is necessary or in case of contraindications for 
corticosteroids, steroidsparing immunosuppressive drugs such as methotrexate 
(MTX), mycophenolate mofetil (MMF), azathioprine, cyclosporine, and sometimes 
cyclophosphamide are used, often in combination with low-dose corticosteroids. 
In refractory or therapy-resistant ocular inflammatory eye disease, tumor 
necrosis factor (TNF-α) antagonists such as infliximab and adalimumab 
increasingly are be-ing used,8 –14 sometimes in combination with other 
steroid- sparing immunosuppressive drugs. Because of the low incidence and 
prevalence of scleritis,1 the numbers of studies with large numbers of patients 
are limited,15 and well-documented clinical experience in predicting the course 
of the disease and guidelines for its treatment are not widely available. This 
retrospective study examined patient characteristics, visual outcomes, ocular 
complications, and efficacy of treatment for 104 scleritis patients. Furthermore, 
prognostic factors that correlated with a worse visual prognosis, steroid-sparing 






One hundred four patients diagnosed with scleritis between 1992 and 2011 at 
the University Medical Centers of Groningen, The Netherlands (n = 64), and of 
Utrecht, The Netherlands (n = 40), were analyzed. The Medical Ethical Committee 
of the University Medical Center of Groningen ruled that approval was not 
required for this study. Patients were identified by searching on the diagnosis 
code ‘scleritis’ in the digital uveitis databases of both centers. If in doubt about 
the diagnosis of scleritis, the opinion of an academic uveitis specialist based 
on the patient’s file was decisive. Only patients with a follow-up of more than 
3 months were included. The Watson and Hayreh classification was used for 
the type of scleritis, with the diagnosis of posterior scleritis or panscleritis 
confirmed by ultrasound. Necrotizing scleritis was classified as necrotizing 
(with inflammation) or scleromalacia perforans (without inflammation). 
The decimal equivalent of the Snellen visual acuity of both eyes at presentation 
and at last follow-up and the maximum visual acuity were recorded. This 
visual acuity was converted to logarithm of the minimum angle of resolution 
units and, after computation of mean and standard deviation, was calculated 
back to Snellen decimal acuity. Loss of visual acuity was defined as a decrease 
of more than 2 lines on the Snellen chart. No light perception in the affected 
eye was defined as blindness. Patients whose loss of visual acuity was not a 
result of the scleritis were excluded from this analysis. Corneal complications 
were characterized as ulcerative or peripheral thinning. Uveitis was diagnosed 
when cells could be observed in the anterior chamber or in the vitreous and 
was classified as anterior uveitis, intermediate uveitis, posterior uveitis, or 
panuveitis. The lens was graded as clear, having cataract, pseudophakic, or 
having posterior capsule opacification. The presence of cystoid macular edema 
was noted only if confirmed by fluorescein angiography or optical coherence 
tomography. Serous retinal detachments were diagnosed by funduscopy or 
ultrasound. Ocular hypertension was defined as an intraocular pressure of more 
than 21 mmHg, and the given treatment was recorded. 
All 104 patients underwent screening for underlying systemic disease, and 
88 patients underwent screening in accordance to the guidelines of the 
Dutch Ophthalmologic Society: (http://www.oogheelkunde.org/uploads/fl/
ve/flvem3mKxt8ThFFYVhn8GQ/Richtlijn- voor-diagnostiek-en-behandeling-
van-uveitis-15-mei-2007-1.pdf; accessed January 23, 2012). The other 16 
patients were screened by a tailored approach or screening was not performed 
when scleritis was considered a manifestation of a known systemic disease. 
Laboratory testing included blood and urine tests, chest radiography, and 
tuberculin skin testing. Serologic and general laboratory tests included complete 
blood count, white cell differential, inflammatory parameters (C-reactive protein 
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and erythrocyte sedimentation rate), liver and kidney function tests, antinuclear 
antibody analysis, antineutrophil cytoplasmic antibody (ANCA) analysis, and 
rheumatoid factor analysis. Other tests, such as Treponema pallidum antibody 
titers, Lyme antibody titers, angiotensin-converting enzyme, and human 
leukocyte antigen (HLA)-B27, were not obtained routinely, but were based on 
history and physical examination. In case of an underlying systemic disease, the 
patient was diagnosed by a specialist in that area. Associated systemic diseases 
were classified as infectious or autoimmune. The most common autoimmune 
and infectious causes were recorded. The rare causes were listed per patient. 
When known, the smoking status was included in the analysis.
In these patients, treatment was administered mainly according to a stepladder 
approach: In infectious causes, the cause of the infection was treated. In 
autoimmune nonnecrotizing scleritis, NSAIDs were given as a first choice, 
and in case of NSAID failure, high-dose corticosteroids were given. In case 
corticosteroids could not be reduced to a dosage of less than 10 mg daily, a 
corticosteroid-sparing immunosuppressive drug was considered, which was 
usually MTX. Methotrexate was started orally in a dosage between 7.5 and 15 mg 
weekly and was increased according to clinical response to a maximum of 25 
mg weekly via subcutaneous injection or 30 mg weekly orally. In most patients, 
this was carried out in at least 3 steps each with an interval of at least 2 months. 
In case of MTX failure, MMF was started, and in case this failed as well, a TNF-α 
antagonist was introduced. In case of necrotizing scleritis, corticosteroids and 
corticosteroid-sparing medication were started immediately.
Treatment success was defined as a subjective and an observable inactive 
disease for longer than 3 months using less than 10 mg daily oral prednisone 
alone or in combination with corticosteroidsparing drugs. A relapse was 
defined as a recurrence of the scleritis after a quiet episode described in the 
patient file. The total followup time (disease duration including treatment of 
secondary complications) and time to treatment success were documented. 
In case of a multiple medication regimen, a stepwise approach was used and 
the time to control of the inflammation was related to the last added systemic 
immunosuppressive drug. In patients who were already receiving systemic 
medication for a systemic disease at presentation, the change in medication or 
dosage responsible for treatment success was recorded.
How clinical characteristics, visual outcome, ocular complications, and 
differences in treatment affected outcome was analyzed using SPSS software 
version 18 (SPSS, Inc, Chicago, IL) based on 3 end points: loss of visual acuity, 
treatment with steroid-sparing immunosuppressive drugs, or longer disease 
duration. A P value of 0.05 or less was considered to be statistically significant. 





for categorical variables, the Student t test for comparing independent groups 
with a continuous variable, and the Spearman bivariate correlation coefficient 
for analysis of a correlation between 2 continuous variables were used. These 
findings were verified and confirmed by logistic and linear regression models. 
Two patients were identified by SPSS analysis (boxplot) as extreme outliers (more 
than 3.0 times the interquartile range above the third quartile) and therefore 
were excluded from the analysis. Kaplan-Meier curves were used to display 
graphically the type of treatment related to time to disease remission.
RESULTS
Patients’ characteristics are summarized in Table 1. Of the 104 scleritis patients, 
63 (60.6%) were female. Mean follow-up was 38.2 months (range, 3–154 months). 
Mean age was 51.5 years (range, 18–91 years). The 6 patients with necrotizing 
disease were the oldest; the 4 patients with posterior disease were the youngest. 
The latter were all female. Most patients (n = 64) had unilateral disease. Diffuse 
anterior scleritis was the most common type of scleritis, followed by panscleritis. 
Table 2 summarizes ocular complications. Complications were observed in 88 (84.6%) 
patients. The largest percentage of complications were seen in necrotizing scleritis 
patients. Uveitis was the most common complication (n = 47). Cataract formation 
was documented in 30 patients, whereas 6 patients were pseudophakic at presenta-
tion. Posterior scleral swelling as shown by ultrasound was found in 31 patients, 
and 2 patients had posterior scleral thickening related to severe anterior scleritis. 
Table 3 shows the loss of visual acuity related to type of scleritis and severity. A 
loss of more than 2 lines of Snellen acuity occurred in 23 patients (Table 3), 3 of 
whom became blind (no light perception visual acuity) because of scleritis. All 3 
of the latter patients had necrotizing scleritis. In 2 of these patients, there was 
an association with Wegener’s disease, and the third patient had a scleromalacia 
perforans without known underlying systemic disease. 
The 23 patients with a decrease in visual acuity had an average Snellen visual 
acuity standard deviation (SD) at presentation of 0.9 ± 0.34, and their final average 
Snellen visual acuity ±SD was 0.66±0.38. The remaining 81 patients showed, on 
average, an increase in visual acuity of 0.17 (range, 0.007–1.0).
Of the 43 patients (Table 2) with an intraocular pressure to more than 21 mmHg, 
26 patients were diagnosed as steroid responders because of the use of local 
or systemic corticosteroids. Because of the elevation in intraocular pressure, 20 
patients were administered antiglaucoma medication, and glaucoma surgery 
















N total 36 20 6 9 4 3 26 104 
Bilateral 18 5 3 3 1 0 10 40 (38.5%) 
Ocular  
complications 
31 11 6 7 4 3 26 88 (84.6%) 
Corneal  
Thinning 
2 2 2 2 0 0 1 9 (8.7%) 
Corneal ulcerative  8 2 4 2 1 0 2 19 (18.3%) 
Uveitis 20 1 4 4 2 1 15 47 (45.6%) 
Anterior uveitis 18 1 2 3 2 1 10 37 (35.9%) 
Intermediate uveitis 2 0 0 1 0 0 1 4 (3.9%) 
Panuveitis 0 0 2 0 0 0 4 6 (5.8%) 
Cataract 10 2 4 5 1 0 8 30 (28.8%) 
CME 5 1 3 1 1 0 11 22 (21.4%) 
Exudative retinal 
detachment 
0 0 2 1 0 0 6 9 (8.7%) 
T-Sign (US) 0 1 1 0 4 0 25 31 (30.1%) 
VA-loss* 10 3 2 4 0 0 4 23 (22.1%) 
Ocular hypertension§  13 8 3 3 0 2 14 43 (41.7%) 
Steroidresponder 9 4 2 2 0 2 7 26 (25.2%) 
CME =  cystoid macular edema; US = ultrasound; VA = visual acuity. *Decrease in visual acuity of 2 
Snellen lines or more (worse of the 2 eyes) at the end of the follow up. §  Intra-ocular pressure higher 
than 21 mmHg 
 
Table 2. Ocular complications 
















N total  36 20 6 9 4 3 26 104 
Loss of ≥ 2  
Snellen lines* 
7 1  1   1 10 (9.6%) 
Severe loss > 3  
Snellen lines§ 
3 2  2   3 10 (9.6%) 
NLP   2 1    3 (2.9%) 
NLP = No light perception. * Decrease in visual acuity of ≥ 2 Snellen lines at the end of the follow up 
period. § Decrease in visual acuity of > 3 Snellen lines at the end of the follow up period 
 
Diagnosis/type N Mean age (range) Male N (%) Female N (%) Bilateral N (%)  
Scleritis total 104 51.5 (18.6 - 91.8) 41 (39.8%) 63 (60.6 %) 40 (38.5%) 
Anterior scleritis  71 51.9 (25.4 – 91.8) 29 (40.8%) 42 (59.2%) 29 (40.8%) 
Diffuse 36 51.4 (25.4 – 79.5) 13 (36.1%) 23 (63.9%) 18 (50%) 
Nodular 20 50.1 (30.5 – 67) 7 (35%) 13 (65%) 5 (25%) 
Necrotizing 6 62.5 (41.3 – 91.8) 3 (50%) 3 (50%) 3 (50%) 
Scleromalacia 9 50.9 (38.6 – 71.6) 6 (66.7%) 3 (33.3%) 3 (33.3%) 
 Posterior scleritis (incl SINS) 7 47.9 (18.6 – 73.1) 2 (28.6%) 5 (71.4%) 1 (14.3%) 
Posterior 4 39.4 (18.6 – 56.5) 0 4 1 (25%) 
Surgery induced (SINS) 3 59.2 (39.8 – 73.1) 2 (66.7%) 1 (33.3%) 0 
 Panscleritis (anterior + posterior) 26 51.4 (25.6 – 69.2) 10 (38.5%) 16 (61.5%) 10 (38.5%) 
 





Underlying systemic diseases are summarized in Table 4. In 34 (32.7%) patients, 
an underlying cause was found. Within the noninfectious group, rheumatoid 
arthritis (RA) was the most frequently identified underlying disease (n = 14), 
followed by Wegener’s disease in 7 patients. In most of the patients (n = 26) with 
an underlying noninfectious cause, the disease was already diagnosed before the 
first episode of scleritis. In 2 patients, Wegener’s disease was found by screening, 
and in 1 patient, RA was found by screening, and in another it manifested during 
follow-up. In 3patients, a likely infectious cause of the scleritis was found by 
screening (Table 4). 
Screening according to the guidelines of the Dutch Ophthalmologic Society 
(http://www.oogheelkunde.org/uploads/fl/ve/flvem3mKxt8ThFFYVhn8GQ/
Richtlijn-voor-diagnostiek-en-behandeling-van-uveitis-15-mei-2007-1.pdf; 
accessed January 23, 2012) was performed in 88 patients. The other 16 patients 
were screened by a tailored approach.
Inflammatory parameters (CRP and ESR) were raised in 52 of the 93 tested 
patients. In 4 of the 46 tested patients, HLA-B27 positivity was found. Lues 
serologic level was tested in 62 patients, and in 1 patient, Treponema pallidum 
antibodies were found. Elevated antinuclear antibody titers were found in 22 
of the 79 patients tested. Seven of these patients had an autoimmune disease. 
Rheumatoid factors were demonstrated in 11 of 73tested patients; 5 of these 
patients had RA. P or c-ANCA autoantibodies were found in 12 of the 80 patients 
tested. In 5 of 7 patients with Wegener’s disease, an increased c-ANCA titer 
was found. In 64 patients, the angiotensin converting enzyme (ACE) level was 
determined, 1 of which was out of normal range. In 82 patients, chest radiography 
was performed. In 7 of them, abnormalities were found, and in 3 cases, there was 
a probable association between the findings and scleritis. 
Table 4. Underlying systemic disease









Total n (%) 34 (32.7%) 26 (25%) 6 (5.8%) 2 (1.9%) 
Infectious 3 (2.9%)  3 (2.9%)  
Herpes zoster 2  2  
Lues/syfilis 1  1  
Non-infectious 31 (29.8%) 26 (25%) 3 (2.9%) 2 (1.9%) 
Rheumatoid arthritis 14 12 1 1 
Wegener’s granulomatosis 7 5 2  
Inflammatory bowel disease 3 3   
Behçet’s disease 2 2   
Myastenia Gravis 1 1   
Polyarteritis Nodosa 1 1   
Relapsing Polychondritis 2 1  1 




To describe and analyze efficacy of treatment, medication at presentation and 
medication used for the treatment of scleritis are summarized in Tables 5 and 
6. At presentation, 31 patients were treated with combinations of different 
drugs. In 23 patients, NSAIDs were combined with topical steroids, and MTX was 
combined with NSAIDs at presentation in 6 patients. Mycophenolate mofetil was 
combined with MTX in 1 patient, and another patient was treated with topical 
steroids, topical NSAIDs, and antibiotic eyedrops at presentation. None of the 
patients was taking oral corticosteroids at presentation, and 49 patients were not 
treated at presentation (Table 5). 
Most of the patients (n = 42) who were treated with NSAIDs had no underlying 
disease (n = 32). Of the 42 patients treated with NSAIDs, 33 patients also were 
treated with topical steroids (Table 5). Subconjunctival triamcinolone acetonide 
injections were used in 3 patients with diffuse anterior scleritis; of these, 1 patient 
achieved disease remission after 3 subconjunctival injections in 47.1 weeks. 
Oral corticosteroids were used in 64 patients (Table 6), usually in combination 
with local steroids (n = 52) and sometimes incombination with NSAIDs (n = 8). 
For patients who used oral corticosteroids for maintenance, the dosage varied 
between 5 and 20 mg. On average, patients used more than 7.5 mg daily oral 
corticosteroids for a mean ±SD of 65 ±72.4 weeks (median, 42 weeks). 
Methotrexate was used as treatment in 36 patients (Table 6). The mean dose of MTX 
was 19 mg weekly (median, 20 mg; range, 10–30 mg), with 1 patient using 30 mg 
weekly. All patients received folic acid supplementation 24 to 48 hours after their 
weekly dose of MTX. Treatment success was achieved in 17 of 36 patients with a 
mean dose of 18 mg weekly (median, 17.5 mg weekly). Within this group, there was 
no relationship between MTX dosage and chance of treatment success. However, the 
patients who received a higher dose of MTX (mean, 26.3 mg weekly) showed a smaller 
range in time to treatment success (range, 80–215 weeks) than the patients who 
were treated with a lower dose (mean, 15.6 mg weekly) of MTX (range, 21–336 weeks).
Table 5. medication at presentation*
Medication N (%) 
None 49 (47.5%) 
Local steroids 46 (44.2%) 
NSAIDs 31 (29.8%) 
MTX 6 (5.8%) 
AZA 4 (3.8%) 
MMF 1 (1%) 
Cyclosporine 1 (%) 
TNF-α antagonist 3 (2.9%) 
Antiviral 2 (2.9%) 
Antibiotics 5 (4.8%) 
AZA = azathioprine; MMF = mycophenolate 
mofetil: MTX = methotrexate; NSAIDs =  
nonsteroidal anti-inflammatory drugs; TNF- 
α = tumor necrosis factor α. * 31 patients 






Mycophenolate mofetil was used in 10 patients as a steroidsparing immuno-
suppressive treatment (Table 6); 5 of these patients were treated with MMF 
after MTX failure. Treatment success was achieved in 5 patients in a mean 
±SD of 65.3 ±37.4 weeks (median, 73 weeks). Azathioprine was added to the 
immunosuppressive regimen in 13 patients; treatment success was achieved in 
only 1 patient in 192.8 weeks. In 3 patients, a combination of immunosuppressive 
drugs including azathioprine resulted in treatment success. In these cases, 
treatment success was attributed to the last added immunosuppressive drug.
In 5 of the 11 patients who received a TNF-α antagonist, treatment success 
was achieved in 32.6 weeks (SD, 21.8 weeks;median, 28.9 weeks; Table 6). The 
remaining 6 patients had no treatment success, which was ascribed to a short 
follow-up time or a change in treatment. Most patients were treated with 1 or 2 other 
immunosuppressives in addition to a TNF-α antagonist. Only 1patient achieved 
treatment success with adalimumab as monotherapy. The 4 other patients achieved 
treatment success with a combination of etanercept and MTX, adalimumab and 
MTX, or adalimumab combined with MTX and cyclosporine (n = 2). One patient 
was started on infliximab, but still had active disease at the end of the follow-up. 
Of the 8 patients treated with cyclophosphamide (Table 6), 6 had Wegener’s disease. 
Control of inflammation was reached in 4 of these patients with a combination of 
oral corticosteroids, cyclophosphamide, and azathioprine or MMF in a mean±SD of 
68 ± 75.7 weeks. Of the other 4 patients, 1 patient became blind (no light perception 
visual acuity), 1 patient died during follow-up, 1 patient had active disease, and 1 
patient had control of the inflammation with a high dose of oral corticosteroids.
There were 12 patients without described treatment success. Five of these 12 
patients had no known systemic disease, and the other 7 patients had RA (n = 2), 
Wegener’s disease (n = 3), or relapsing polychondritis (n = 2). Four patients died 
during followup; 2 of them had RA and 1 died of ovarian carcinoma. The time 
and chance of treatment success related to the type of treatment was displayed 
graphically using Kaplan-Meier curves (Fig 1). In 27 patients, medication was 
discontinued or changed because of side effects. Overall, 60 patients relapsed 
1.65 times (range, 0–5; median, 1). 
Medication N Remission N % Mean time till remission (weeks) 
NSAID 42 36 (85.7%) 48.8 (median 19.1, min-max 12 – 228.6) 
Oral corticosteroids 64 19 (29.7%) 83.9 (median 56.7, min-max 12 – 301.1) 
MTX 36 17 (47.2%) 103.7 (median 93.6, min-max 21.9 – 336.7) 
AZA 13 1 (7.7%) 192.8 
TNF-α antagonist 11 5 (45.5%) 32.6 (median 28.9, min-max 14 – 69.6) 
MMF 10 5 (50%) 65.3 (median 73, min-max 26.3 – 115.6) 
Cyclophosphamide 8 4 (50%) 68 (median 35.1, min-max 21.4 – 180.4) 
AZA = azathioprine; MMF = mycophenolate mofetil: MTX = methotrexate; NSAIDs = nonsteroidal 
anti-inflammatory drugs; TNF- α = tumor necrosis factor α. 
 
Table 6. Medication used for scleritis treatment
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In the analysis of the prognostic factors (Table 7), patients with a bilateral 
scleritis at any time had a worse prognosis for all 3 end points. Patients with 
underlying systemic disease more often demonstrated loss of visual acuity 
and were more likely to be treated with steroid-sparing immunosuppressive 
drugs. In the analysis for disease duration, 2 patients had an extremely long 
duration of disease and were identified by SPSS software (boxplot) as extreme 
outliers (more than 3.0 times the interquartile range above the third quartile), 
and therefore they were excluded from this analysis. This analysis showed that 
patients who had scleritis for a longer period at presentation also had a longer 
disease duration after presentation. 
These different prognostic factors were confirmed by logistic and linear 
regression models for interrelationships and influence of the different factors. 
In addition to this, the multivariate linear model for disease duration found 
Figure 1. Kaplan-Meier curves showing the time and chance of 
treatment success related to the type of treatment. 1 = Tumor necrosis 
factor-alpha antagonists, 2 = Cyclophosphamide, 3 = Methotrexate, 4 = 
Mycophenolate mofetil, 5 = Nonsteroidal anti-inflammatory drugs, 6 = 
Oral corticosteroids.
Table 7. Prognostic factors
Characteristic (N) % Visual- acuity  
loss, P value (N) 
Steroid-sparing, 
P value (N) 
Disease duration, 
 P value (N) § 
Gender (female/male) 61/43 NS‡ NS‡ NS† 
Duration of symptoms (wks),  
no. (range) presentation 
21.7 (1-286) NS†  NS† P=<0.000*  
Smoking   41 (42.6%) NS‡ (10)  NS‡ (21)  NS† 
Underlying systemic disease 34 (32.7%) P=0.024‡ (12)   P=<0.000‡ (25) NS† 
Bilateral scleritis 40 (38.5%) P=<0.000‡ (17)  P=0.002‡ (26) P=<0.000† 
Uveitis 47 (45.6%) NS‡ (12)  NS‡ (24)  NS† 
NS = Not significant, ‡ Chi-square test. † Students t-test. * Bivariate correlation. § Two extreme 
outliers were excluded from this analysis. One patient had a scleritis related to Wegener’s disease, 







that men—although fewer—had a longer disease duration. To investigate the 
effect of a longer disease duration on the risk of loss of visual acuity, a separate 
multivariate inear model was used. In this model, a longer disease duration was 
not predictive of loss of visual acuity. 
This analysis suggests that the strongest predictor for a worse prognosis is 
bilateral disease at any time. Patients with bilateral disease lost significantly 
more visual acuity, were treated significantly more often with steroid-sparing 
immunosuppressive drugs, and had a significantly longer disease duration.
DISCUSSION
Within this cohort, 23 patients (22.1 %) lost more than two lines of visual acuity on 
the Snellen-chart. This in contrast to the 81 patients (77.9 %) who gained visual 
acuity or lost less than 2 lines on the Snellen-chart. Most patients with a loss 
of visual acuity in our group (n=10) had a diffuse anterior scleritis. Necrotizing 
scleritis was the most threatening variant of scleritis. Of the 15 patients with 
necrotizing scleritis, 3 had a final visual acuity of no light perception and 2 lost 
more than 3 Snellen lines of visual acuity. In contrast to some other studies, 5, 16 
panscleritis had a good prognosis and no higher association with an underlying 
disease. Although these findings regarding visual acuities should be interpreted 
cautiously in a retrospective study 17, 18, they are in concordance with the literature 
where loss of visual acuity is found in 15.9 to 37 % of the patients with scleritis 
1, 16,19, 20. 
Screening of scleritis patients for an underlying systemic disease should be 
aimed at the high-impact diseases such as RA and Wegener’s disease. The same 
holds true for infectious causes: They should be identified early on because they 
need a different therapeutic approach. In most of the current patients, systemic 
disease had already been diagnosed before scleritis onset. in few of them, this 
was newly identified by screening, and in even fewer patients systemic disease 
became manifest during follow-up. Screening for HLA-B27 positivity seems 
questionable, because an occurrence of HLA-B27 positivity equal to that in the 
normal population (8%) was found and because HLA-association with scleritis is 
rarely described in the literature 21 - 23. Also, the use of screening for sarcoidosis 
is not evident, since this is considered a rare cause of scleritis 5, 24, and in this 
study only one patient had elevated ACE-levels, without systemic manifestations 
of sarcoidosis. These findings suggest that customizing the screening for each 
patient seems an approach by which more useful clinical information can be 
obtained at lower costs.
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In the scleritis patients, MTX was the most frequently used primary steroid-
sparing immunosuppressive drug. The dosage of MTX did not influence the 
treatment success rate, but it had an effect on the range in time span to reach 
treatment success, with a lower range in de maximally treated group. The time 
to treatment success of MTX in our study was long, but it is comparable to that 
in other reports on scleritis 25. However, the time to success of MTX treatment in 
this study was considerably longer than the reported time to treatment success 
of MTX in uveitis eyes 26. 
Reduction in time to treatment success of MTX could be attempted by introducing 
a quicker dose escalation scheme including a faster switch to subcutaneous 
administration. The latter will result in a better bioavailability of the drug, 
particularly in higher MTX doses 27 - 30.
In rheumatic disorders it is recommended to start with 10-15 mg weekly, with 
an escalation of 5 mg every 2-4 weeks up to 20-30 mg weekly, depending on 
clinical response and tolerance, whereas subcutaneous administration should 
be considered in case of an inadequate response or intolerance 29. Such schemes 
are currently being used in the treatment of RA-patients and have resulted in a 
reduction of the time to treatment success and a better steroid-sparing effect 27 - 
29. It has been shown that subcutaneous administration of MTX is equally as well 
tolerated as oral administration 28.
Reducing time to reach the maximum MTX dose will probably lead to a reduction 
in time to treatment success in scleritis patients. Also, MTX failure will be sooner 
evident, so that therapy can be switched at an earlier point in time. A reduction in 
time to treatment success will probably also reduce ocular complications, which 
mainly are the result of active disease, steroid use, or a combination of both. 
Whether more patients can be successfully treated with monotherapy is an issue 
beyond the scope of this study and one that could be studied in a comparative study.
Mycophenolate mofetil seems a viable option after MTX-failure because it can 
induce treatment success in an additional 50 % of the patients. It is open to 
discussion whether MMF in selected patients is preferable as primary therapy 
based on underlying systemic disease or susceptibility to side effects. However, 
the availability of this option also depends on local healthcare policies.
In case both options fail, TNF-α antagonists can induce control of inflammation 
in a further half of the patients. In case of TNF-α antagonists, time to treatment 
success seems to be much shorter than that needed for MTX and MMF. This 
suggests a more effective mechanism of action compared to MTX and MMF. 
Whether TNF-α antagonists can be administered as monotherapy, cannot be 





regard to TNF-α antagonists, it is not known presently which drug is preferable in 
the treatment of scleritis, and long-term effectiveness needs to be established as 
well. Most reports are on infliximab, a humanized chimeric monoclonal antibody, 
which was the first TNF-α antagonist introduced 8, 10, 13, 14. Several small case-
reports describe that rituximab, a genetically engineered chimeric monoclonal 
antibody that recognizes CD20 on mature B lymphocytes can be successful 
in severe recalcitrant forms of scleritis 9, 11, 12. This potential effectiveness is 
supported by 1 study 19 of a small number of eyes enucleated because of severe 
necrotizing auto-immune scleritis that showed CD20 positive cells along with 
plasma cells as major components of the inflammatory infiltrate. Finally, a 
case-report of a patient with nodular scleritis illustrates that adalimumab, a 
humanized monoclonal antibody against soluble and membrane-bound TNF-α, 
may be effective as well 13.
Within the present cohort, scleritis seems to be divided into 2 variants. A mild 
form which is responding well to NSAIDs and a more severe or recalcitrant 
variant that required other types of treatment. Low-dose corticosteroids as 
monotherapy seemed to be effective in only a minority of these patients. Because 
most patients in the severe group needed steroid-sparing immunosuppressive 
drugs, the threshold to start these should be low. Globally, for each steroid-sparing 
immunosuppressive drug, treatment success was achieved approximately half 
of the patients. Azathioprine seems to be an exception because this drug was 
much less effective in the present study. 
Assessing the severity of scleritis at an early stage is important for an adequate 
choice of treatment regimen. Within this patient group necrotizing scleritis, 
male gender, a longer period of complaints at presentation, systemic disease, 
and bilateral disease at any time indicated a worse prognosis. By multivariate 
regression analysis, bilateral disease was the strongest predictor of worse 
prognosis. Patients with these characteristics at presentation had more loss 
of visual acuity, longer disease duration and were more often treated with 
steroid sparing immunosuppressive medication. Risk factors for visual loss or 
prolonged treatment in the literature include necrotizing or posterior scleritis 
31, underlying systemic disease 15, corneal involvement 32, positive results for 
c-ANCA 20, a combination of anterior and posterior scleritis 16 and a posterior 
scleritis at an older age than 50 years 16. With regard to necrotizing scleritis and 
systemic disease, the present results were in agreement with dose reported in 
the literature. Most of these factors are easy to observ at presentation or during 
the course of the disease and contribute to an early recognition of a more severe 
form of scleritis. In contrast, the scleritis scoring system proposed by McCluskey 




However, the results of the current study are limited by the fact that the study 
was retrospective, the numbers of patients were small in some subgroups, there 
was a large variability in follow up and the inclusion period was relatively long 17, 
18. Also, the Snellen visual acuities were not obtained according to a standardized 
protocol and our study was conducted in 2 subspecialty clinics at university 
hospitals and therefore this population does not represent the total spectrum 
of scleritis. Regarding treatment; there is a bias towards personal experience 
and preferences of the ophthalmologists of the two university hospital centers 
and there is an unknown influence on treatment of the health insurance 
politics in the Netherlands. Despite this, the authors believe that they can make 
contributions and recommendations for the improvement of care for scleritis 
patients by sharing our treatment experiences, indicating prognostic factors and 
advising on steps to optimize treatment regimens.
In conclusion, these data shows that scleritis often is a severe, vision threatening, 
and chronic eye disease. Patients with a mild form of scleritis in most cases are 
treated adequately with oral NSAIDs. Patients with more severe or recalcitrant 
forms of scleritis can benefit from a more aggressive treatment strategy. Clinical 
features indicating a more severe form of scleritis make a fast recognition of 
the disease possible. Adequate treatment based on the severity of the scleritis 
and a timely switch to steroid-sparing immunosuppressive drugs can reduce 
total treatment time. Using an appropriate MTX dose-escalation scheme and an 
earlier switch to subcutaneous administration seems advisable in patients with 
non-infectious recalcitrant scleritis. Azathioprine should be avoided in patients 
with scleritis. After MTX failure, MMF is a good option as a secondary steroid-
sparing immunosuppressive drug. Tumor necrosis factor-α antagonists may be 
a viable option for patients with noninfectious, recalcitrant scleritis who are not 
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